Mahmoud Ghazzi

Over the past 25 years, he has held several executive leadership roles that cover the spectrum of Drug Development including President, Global Development Head, Chief Medical Advisor, Medicine Development Center Head, and Therapeutic Area Head. His most recent role was President, Daiichi-Sankyo Pharmaceutical Development, and Global Development Head, Daiichi-Sankyo Research & Development.

Throughout his career, Dr. Ghazzi has developed portfolios, managed drug development pipelines globally, and advised and led therapeutic area strategies, resources, and talents. He has managed team leaders, physicians, scientists, regulatory strategists, and project managers. Dr. Ghazzi has been responsible for several Global Regulatory submissions and participated in regulatory interactions including Advisory Committee Meetings.

At MMS, Dr. Ghazzi supports internal teams and MMS clients with clinical and regulatory strategy and execution particularly in the areas of cardiovascular and metabolic diseases. He provides independent expert advice for Clinical Development, Regulatory, Safety and Pharmacovigilance, and portfolio strategy including support for drug safety monitoring boards. Dr. Ghazzi earned his MD from the School of Medicine at Damascus University in Syria and a MPH degree, as well as a Ph.D. in Bioengineering, from the University of Michigan.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization